356069-16-4Relevant academic research and scientific papers
Synthesis of 2H- and 13C-labelled sunitinib and its primary metabolite
Elsinghorst, Paul W.,Guetschow, Michael
, p. 360 - 365 (2009)
Sunitinib (Sutent, Pfizer) was approved in 2006 for the treatment of gastrointestinal and renal cancer. Isotope-labelled derivatives have already been prepared for PET and ADME radiography. The preparation of 13C- and 2H-labelled internal standards of sunitinib (SU11248) and its primary metabolite (SU12662) for LC-MS analysis of human blood samples is presented. Copyright
Peptide-Drug conjugate gnrh-sunitinib targets angiogenesis selectively at the site of action to inhibit tumor growth
Argyros, Orestis,Karampelas, Theodoros,Asvos, Xenophon,Varela, Aimilia,Sayyad, Nisar,Papakyriakou, Athanasios,Davos, Constantinos H.,Tzakos, Andreas G.,Fokas, Demosthenes,Tamvakopoulos, Constantin
, p. 1181 - 1192 (2016/04/05)
The potential to heighten the efficacy of antiangiogenic agents was explored in this study based on active targeting of tumor cells overexpressing the gonadotropin-releasing hormone receptor (GnRH-R). The rational design pursued focused on five analogues
